💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Clindamycin

CHEMBL1753 Phase 4 Approuvé Small molecule
Half-Life
2-3 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
425.0 g/mol
LogP
2.2
Phase
4

An antibiotic that stops bacterial growth by blocking protein synthesis, effective against a wide range of skin, respiratory, and soft tissue infections. It is particularly valued for treating infections caused by anaerobic bacteria and certain drug-resistant organisms.

Masse moléculaire

424,9830 g/mol

LogP

2,20

TPSA

128,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Endometriosis Pain Management Rheumatoid Arthritis Asthma Insomnia Obesity Lymphoma Hypertension Breast Cancer Chronic Pain Malaria Heart Failure Colorectal Cancer Leukemia

Classes de médicaments

J — J - Antiinfectives for Systemic Use

Mécanisme d'action

Binds 50S ribosomal subunit inhibiting protein synthesis.

Pharmacokinetics (PK)

Half-Life 2-3 hours

Pharmacodynamics (PD)

Mécanisme

Binds 50S ribosomal subunit inhibiting protein synthesis.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H33ClN2O5S

                    

                    
                    

                        
HBD / HBA

                        
4 / 7

                    

                    
                    

                        
Liaisons Rotatives

                        
7

                    

                    
                    
                    

                        
Atomes Lourds

                        
27

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Clindamycin + Methotrexate
                            
                        

                        
                        
Clindamycin may reduce renal tubular secretion of methotrexate, raising methotrexate levels and increasing the risk of haematological and GI toxicity.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Clindamycin + Warfarin
                            
                        

                        
                        
Clindamycin may enhance the anticoagulant effect of warfarin by disrupting vitamin K-producing gut flora, leading to unpredictable INR elevations and increased bleeding risk during and shortly after the antibiotic course.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
An antibiotic that stops bacterial growth by blocking protein synthesis, effective against a wide range of skin, respiratory, and soft tissue infections. It is particularly valued for treating infections caused by anaerobic bacteria and certain drug-resistant organisms.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds 50S ribosomal subunit inhibiting protein synthesis.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Clindamycin: Half-life: 2-3 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Clindamycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Amoxicillin
                            Small molecule
                        
                        
                        
                            Azithromycin
                            Small molecule
                        
                        
                        
                            Ciprofloxacin
                            Small molecule
                        
                        
                        
                            Doxycycline
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1753.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 446598.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.